1 in 6 men will be diagnosed with prostate cancer in their lifetime. The good news is that when detected early, prostate cancer is one of the most successfully treated types of cancer.
The challenge is that the current method of screening – the prostate-specific antigen (PSA) test, looks at just one data point in a complex equation. The test identifies levels of PSA, a protein made in the prostate, and flags higher levels for prostate cancer risk and further testing, including biopsy (1).
Higher PSA levels can indicate prostate cancer, but they can also be caused by vigorous exercise, recent sexual activity, a prostate infection, etc. In fact, biopsies show most ‘positive’ PSA tests are not indicative of clinically significant prostate cancer (2).
The result is that patients may opt for unnecessary, invasive prostate biopsies and treatments with potentially harmful side effects. There is a better way.